COX2 Antibody (YA5631)
(Synonyms: COX 2; COX-2; COX2; Cyclooxygenase 2; Cyclooxygenase 2b; Cyclooxygenase; Cyclooxygenase-2; Cyclooxygenase2; fj02a10; Glucocorticoid-regulated inflammatory cyclooxygenase; Glucocorticoid-regulated inflammatory Prostaglandin G/H synthase; GRIPGHS; hCox 2; Macrophage activation-associated marker protein P71/73; OTTHUMP00000033524; PES-2; PGG/HS; PGH synthase 2; PGH2_HUMAN; PGHS 2; PGHS-2; PGHS2; PHS 2; PHS II; PHS2; Prostaglandin endoperoxide synthase 2; prostaglandin G/H synthase and cyclooxygenase; Prostaglandin endoperoxide synthase 2; Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 2 precursor; Prostaglandin G/H synthase and cyclooxygenase; Prostaglandin G/H synthase; Prostaglandin H2 synthase 2; prostaglandin-endoperoxide synthase 2; prostaglandin G/H synthase and cyclooxygenase; Prostaglandin-endoperoxide synthase 2; PTGS2; ptgs2a; TIS10; TIS10 protein; unp1239; wu:fj02a10)COX2 Antibody (YA5631) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to COX2.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
IHC-P, WB, ICC/IF, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|---|
| Dilution Ratio | 1:200-1000 | 1:500-2000 | 1:100-500 | 1:1000-5000 |
Product Details
COX2 Antibody (YA5631) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to COX2.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 70 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 69 kDa
Synthesized peptide derived from human COX-2 (cyclooxygenase-2) AA range: 500-604
Protein G
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Cyclooxygenase-2 (COX-2) is an inducible enzyme catalyzing the conversion of arachidonic acid to prostaglandin endoperoxides, central to prostanoid biosynthesis and inflammatory signaling[1][2]. Mechanistically, COX-2 activity is regulated by both its catalytic and allosteric subunits, allowing modulation by fatty acids and selective inhibitors, distinguishing it from constitutive COX-1[2]. COX-2 is strongly upregulated in response to pro-inflammatory cytokines, hypoxia, and tumor microenvironment signals, orchestrating prostaglandin E2 (PGE2) production and downstream activation of NF-κB and PI3K-Akt pathways[3][4][5]. In disease models, COX-2 contributes to cancer progression, atherosclerosis, and migraine through modulation of immune responses, vascular smooth muscle activity, and neuronal-glial interactions[6][7][5]. Compared with COX-1, COX-2 expression is more context-dependent and spatially regulated, being highly inducible in endothelial cells, arterial versus venous smooth muscle, and neuronal populations under stress or inflammatory stimuli[8][9][10]. Experimental studies demonstrate COX-2 as a critical mediator of ischemic preconditioning in the heart, providing cardioprotection via PGE2 and PGI2 signaling[11]. Selective COX-2 inhibitors, including synthetic NSAIDs and dual COX/LOX modulators, are utilized to interrogate COX-2 function and develop anti-inflammatory therapies with reduced gastrointestinal and cardiovascular side effects[3][12]. Agonist studies further highlight receptor-mediated induction of COX-2, exemplifying its role in colon carcinoma and trigeminal ganglia models[13][7].
-
Subcellular Localization
Microsome membrane; Peripheral membrane protein; Endoplasmic reticulum membrane; Peripheral membrane protein; Nucleus inner membrane; Peripheral membrane protein; Nucleus outer membrane; Peripheral membrane protein
-
Expression
Induction:By cytokines and mitogens. Up-regulated by IL1B (PubMed:26282205, PubMed:9545330) . Up-regulated by lipopolysaccharide (LPS) (PubMed:9545330) -
Subunit
Homodimer
-
SwissProt ID
-
Synonyms
COX 2; COX-2; COX2; Cyclooxygenase 2; Cyclooxygenase 2b; Cyclooxygenase; Cyclooxygenase-2; Cyclooxygenase2; fj02a10; Glucocorticoid-regulated inflammatory cyclooxygenase; Glucocorticoid-regulated inflammatory Prostaglandin G/H synthase; GRIPGHS; hCox 2; Macrophage activation-associated marker protein P71/73; OTTHUMP00000033524; PES-2; PGG/HS; PGH synthase 2; PGH2_HUMAN; PGHS 2; PGHS-2; PGHS2; PHS 2; PHS II; PHS2; Prostaglandin endoperoxide synthase 2; prostaglandin G/H synthase and cyclooxygenase; Prostaglandin endoperoxide synthase 2; Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 2 precursor; Prostaglandin G/H synthase and cyclooxygenase; Prostaglandin G/H synthase; Prostaglandin H2 synthase 2; prostaglandin-endoperoxide synthase 2; prostaglandin G/H synthase and cyclooxygenase; Prostaglandin-endoperoxide synthase 2; PTGS2; ptgs2a; TIS10; TIS10 protein; unp1239; wu:fj02a10
Documentation
[1]. Smith FG, et al. Cyclooxygenase (COX) Inhibitors and the Newborn Kidney. Pharmaceuticals (Basel). 2012 Oct 25;5(11):1160-76. [Content Brief]
[2]. Ahmadi M, et al. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med Chem. 2022 Feb 14;13(5):471-496. [Content Brief]
[3]. Bolli R, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002 Aug 15;55(3):506-19. [Content Brief]
[4]. Kirkby NS, et al. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One. 2014 Jun 2;9(6):e98165. [Content Brief]
[5]. Segelcke D, et al. The role of the spinal cyclooxygenase (COX) for incisional pain in rats at different developmental stages. Eur J Pain. 2020 Feb;24(2):312-324. [Content Brief]
[6]. Chatzipieris FP, et al. Recent advances in dual COX/LOX inhibitor design (2020-2024). Life. 2026;16(1):163. [Content Brief]
[7]. Yang WL, et al. Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells. Carcinogenesis. 2000 Oct;21(10):1789-93. [Content Brief]
[8]. Hsieh HL, et al. c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J Neuroinflammation. 2012 Jul 2;9:152. [Content Brief]
[9]. Neeb L, et al. IL-1β stimulates COX-2 dependent PGE₂ synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One. 2011 Mar 4;6(3):e17360. [Content Brief]
[11]. Bishop-Bailey D, et al. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1655-61. [Content Brief]
[12]. Majumder M, et al. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation. Mol Cancer Res. 2015 Jun;13(6):1022-33. [Content Brief]
[13]. Scott KF, et al. Functional coupling and differential regulation of the phospholipase A2-cyclooxygenase pathways in inflammation. J Leukoc Biol. 1999 Oct;66(4):535-41. [Content Brief]
[14]. Smith WL, et al. Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2. J Biol Chem. 2019 Feb 1;294(5):1697-1705. [Content Brief]
Powered by Bioz
